Supplementary_final.docx (143.73 kB)

Efficacy and Safety of Glimepiride with or without Linagliptin Treatment in Patients with HNF1A-diabetes (Maturity Onset Diabetes of the Young Type 3): A Randomized, Double-blinded, Placebo-controlled, Crossover Trial (GLIMLINA)

Download (143.73 kB)
figure
posted on 13.07.2020, 17:17 by Alexander S. Christensen, Sofie Hædersdal, Julie Støy, Heidi Storgaard, Ulla Kampmann, Julie L. Forman, Marta Seghieri, Jens J. Holst, Torben Hansen, Filip K. Knop, Tina Vilsbøll
OBJECTIVE

Sulfonylureas are first-line treatment of hepatocyte nuclear factor 1-alpha (HNF1A)-diabetes [maturity onset diabetes of the young type 3], but many patients do not achieve optimal glycemic control without episodes of hypoglycemia. We investigated the combination of the sulfonylurea, glimepiride, and the dipeptidyl peptidase-4 inhibitor, linagliptin, versus glimepiride monotherapy with respect to glycemic variability, glycemic control and risk of hypoglycemia.

RESEARCH DESIGN AND METHODS

In a randomized, double-blinded, crossover trial, patients with HNF1A-diabetes (n = 19, [mean ± SD]; age: 43 ± 14 years; BMI 24.8 ± 2.8 kg/m2; glycated hemoglobin (HbA1c) 7.4 ± 0.2% [57.1 ± 7.3 mmol/mol]) were randomly assigned to treatment with glimepiride + linagliptin 5 mg (16 weeks), wash-out (4 weeks) and glimepiride + placebo (16 weeks) (or vice versa). Glimepiride was titrated targeting a fasting plasma glucose of 4.5-6.0 mM without hypoglycemia. Treatments were evaluated by continuous glucose monitoring (CGM), HbA1c and meal test.

RESULTS

Compared to glimepiride + placebo, glimepiride + linagliptin did not significantly improve the primary endpoint mean amplitude of glycemic excursions (MAGE) ([mean difference] -0.7 mM, P = 0.1540) but displayed significant reductions in coefficient of variation (CV) on CGM (-3.6%, P = 0.0401), HbA1c (-0.5%, P = 0.0048) and glimepiride dose (-0.7 mg/day, P = 0.0099). Beta cell glucose sensitivity (assessed as C-peptide:glucose) during meal test improved with glimepiride + linagliptin. Incidences of hypoglycemia were similar with both treatments.

CONCLUSION

Linagliptin as add-on treatment to glimepiride improved glycemic variability and control without increasing risk of hypoglycemia in patients with HNF1A-diabetes.

Funding

The study was funded by an unrestricted grant from Boehringer Ingelheim, Copenhagen, Denmark.

History

Exports